From Biologics to AI: The Technologies Redefining Ankylosing Spondylitis Treatment

Ankylosing Spondylitis Enters a New Treatment Era

Ankylosing spondylitis is a chronic inflammatory disorder that primarily affects the spine and sacroiliac joints. Persistent inflammation can lead to back pain, stiffness, reduced mobility, and, in advanced cases, spinal fusion.

For years, treatment largely focused on managing inflammation and symptoms. Today, physicians have access to a broader range of targeted therapies designed to address specific inflammatory pathways.

TNF inhibitors remain an important treatment option, while IL-17 inhibitors and newer immune-modulating therapies are creating additional choices for patients who require more targeted approaches.

At the same time, improvements in diagnostic imaging and digital monitoring are helping healthcare professionals identify disease activity and follow treatment responses more closely.

Key Highlights

• The global sector was valued at USD 6.7 billion in 2025.
• It is projected to reach approximately USD 11.83 billion by 2035.
• Growth is expected at a 5.85% CAGR between 2026 and 2035.
• North America accounted for approximately 40% of revenue in 2024.
• Asia-Pacific is expected to record the fastest growth, with a CAGR of around 12%.
• TNF inhibitors held the leading position among drug classes, with approximately 45% share in 2024.
• IL-17 inhibitors are expected to experience strong expansion during the coming years.
• Subcutaneous administration represented approximately 50% of revenue in 2024.
• MRI accounted for around 40% of diagnostic revenue.
• Hospitals represented approximately 45% of end-user revenue in 2024.

Biologics Are Changing the Treatment Landscape

Biologic medicines have transformed the management of ankylosing spondylitis by targeting specific inflammatory pathways.

TNF inhibitors such as adalimumab, infliximab, and etanercept work by blocking tumor necrosis factor, an inflammatory protein associated with disease activity.

Another important development is the growing use of IL-17 inhibitors, including secukinumab and ixekizumab. These therapies target the IL-17A pathway and can help reduce inflammation and improve symptoms.

As research progresses, newer immune-modulating therapies could provide additional options for patients who experience inadequate responses or intolerance to existing treatments.

AI Is Making Diagnosis and Monitoring Smarter

Artificial intelligence is beginning to play a greater role in ankylosing spondylitis care.

AI and machine learning can assist in analyzing X-rays and MRI scans, helping physicians identify subtle inflammatory changes and structural abnormalities. These technologies may also support disease monitoring by identifying patterns that are difficult to detect through conventional analysis alone.

Digital health platforms, wearable sensors, and smartphone applications are creating another layer of patient monitoring. These tools can capture information about mobility, stiffness, pain, and daily activity, allowing healthcare professionals to better understand how patients respond to treatment outside clinical settings.

In the long term, combining imaging, patient data, and AI-based analytics could support more individualized treatment decisions.

MRI Remains a Key Diagnostic Tool

MRI continues to play a central role in early ankylosing spondylitis diagnosis because it can identify inflammatory changes that may not yet be visible through conventional X-rays.

Its ability to visualize soft tissues and inflammatory activity makes MRI particularly valuable when physicians suspect early-stage disease.

Meanwhile, digital spine monitoring tools are emerging as an important complementary technology. Wearable devices and mobile applications could make continuous monitoring more practical while reducing the need for frequent in-person visits.

Blood biomarkers and HLA-B27 genetic testing are also contributing to the broader diagnostic approach.

Targeted Therapies Gain Momentum

The treatment landscape is moving toward greater precision.

Instead of relying on a single treatment pathway, physicians can increasingly consider disease severity, inflammatory activity, treatment response, patient characteristics, and other clinical factors when selecting therapy.

This shift toward personalized treatment is encouraging greater research into:

• IL-17 inhibitors
• JAK inhibitors
• Novel biologic therapies
• Biosimilars
• Biomarker-based treatment selection
• Digital disease monitoring
• Emerging cell and gene therapy approaches

Although several of these technologies remain at different stages of development, they demonstrate the direction in which AS treatment is evolving.